Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan plus Pembrolizumab vs Placebo plus Pembrolizumab in Adjuvant Clear Cell RCC (MK-6482-022)
jRCT2051220030Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in clear cell renal cell carcinoma (ccRCC) comparing Belzutifan + Pembrolizumab with Placebo + Pembrolizumab (2 arms). Primary endpoint: Disease-free survival. Started Jul 2022; status: active, not recruiting.
02
Drugs
belzutifanpembrolizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on jRCT2051220030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220030.